Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19 (ASCCOVID19)

22 giugno 2021 aggiornato da: University Hospital, Bordeaux

As of March 2020, COVID-19 has become a global pandemic, halting athletic competition worldwide.

Reports from China show a high prevalence of cardiac involvement in patients with severe SARS-CoV-2 infection. These cardiac forms were found to be closely associated with adverse outcomes. The use of Magnetic resonance Imaging (MRI) had allowed to show that cardiac dysfunction could be mediated by myocardial inflammation (i.e. myocarditis). The direct implication of the virus was demonstrated with Severe Acute Respiratory Syndrome (SARS)-CoV-2 being detected on myocardial biopsies in a patient with severe heart failure.

The experience with other viruses causing acute myocarditis shows that there is a high rate of undetected injuries. Indeed, although severe heart failure can be present at the acute stage, acute viral myocarditis is most commonly pauci or asymptomatic, but still leaving occult myocardial scars visible on MRI, and exposing to higher risks of ventricular arrhythmia and sudden cardiac death over the long term.

Although athletes are younger and have fewer comorbidities than the general population and therefore are at lower risk for severe disease or death, there is a critical and urgent need to assess the prevalence of occult scars in the population of high-level athletes returning to training after the SARS-CoV-2 pandemia.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

984

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Francia
      • Angoulême, Francia, 16000
        • Training center Soyaux Angoulême XV Rugby
      • Aurillac, Francia, 15000
        • Training Center Stade Aurillacois
      • Bayonne, Francia, 64104
        • Aviron Bayonnais Rugby Pro Training Center
      • Biarritz, Francia, 64200
        • Biarritz Olympique Pays Basque training center
      • Bordeaux, Francia, 33076
        • Bordeaux University Hospital - CRB medical office - Hôpital du Tondu
      • Bordeaux, Francia, 33076
        • Bordeaux University Hospital - Service UDH - Hôpital Pellegrin
      • Brive-la-Gaillarde, Francia, 19100
        • CABCL Rugby Training Center
      • Bègles, Francia, 33130
        • Union Bordeaux-Bègles training center
      • Carcassonne, Francia, 11000
        • US Carcassonne Rugby training center
      • Colomiers, Francia, 31770
        • Union Sportive Colomiers Rugby training center
      • Grenoble, Francia, 38100
        • FC Grenoble Rugby training center
      • La Rochelle, Francia, 17000
        • Stade Rochelais Rugby training center
      • Le Plessis-Robinson, Francia, 92350
        • Racing92 training center
      • Montauban, Francia, 82000
        • AS Montauban Rugby training center
      • Nevers, Francia, 58000
        • US Nevers Rugby training center
      • Paris, Francia, 75016
        • Stade Français training center
      • Pau, Francia, 64000
        • Section Paloise Rugby training center
      • Perpignan, Francia, 66000
        • USAP Training Center
      • Romans-sur-Isère, Francia, 26100
        • Training center Valence Romans Drôme Rugby
      • Saix, Francia, 81710
        • Castres Olympique training center
      • Toulouse, Francia, 31200
        • Stade Toulousain Rugby training center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • High level athlete,
  • Of both sexes and age ≥ 18 years,
  • Affiliated to or beneficiary of a social security system,
  • Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research),
  • Effective method of contraception for women with childbearing capacity.

Exclusion Criteria:

  • Minor,
  • History of ventricular arrhythmia, myocarditis, identified coronary artery disease or documented myocardial fibrosis,
  • Pregnant or breastfeeding women,
  • Person unable to give informed consent,
  • Person deprived of liberty by judicial or administrative decision,
  • Adults subject to a legal protection measure (guardianship, curator, safeguard of justice).

Specific exclusion criteria for the MRI component (Contraindications):

  • Subject with an implantable pacemaker or defibrillator, intraocular metallic foreign body, intracranial metallic clip, pre 6000 Starr-Edwards type cardiac valve prosthesis, or biomedical device such as insulin pump or neurostimulator,
  • Hypersensitivity to gadolinium or to one of the excipients of the contrast product used,
  • Claustrophobic subjects or those unable to remain in an immobile lying position for 30 minutes,
  • Renal insufficiency with creatinine clearance of less than 30 ml/min,
  • A patient whose shoulder width does not allow installation in the MRI machine.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: High-level athletes

High level athletes are rugby players, intervention unit agents of the National Police, sports students.

Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.

The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects.
Test diagnostico: Resting electrocardiogram
An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
Test diagnostico: Stress test
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
Test diagnostico: Cardiac echocardiography
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
Test diagnostico: Cardiac rhythm monitoring
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
Altro: Questionnaire
To determine the rhythmic risk of athletes
Dispositivo: Injected Cardiac MRI

High resolution MRIs is performed on 200 athletes :

  • 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)
  • 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)
Biologico: Blood sampling for biobank

For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.

For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Presence of rhythmic risk markers bye the questionnaire
Lasso di tempo: Day 0
Questionnaire looking for heart palpitations, chest pain/pressure and shortness of breath.
Day 0
Evaluation by resting ECG of rhythmic risk marker : repolarization disorders
Lasso di tempo: Day 0
Presence or absence of repolarization disorders
Day 0
Evaluation by resting ECG of rhythmic risk marker : inverted T waves
Lasso di tempo: Day 0
Presence or absence of inverted T waves
Day 0
Evaluation by resting ECG of rhythmic risk marker : ST segment abnormalities
Lasso di tempo: Day 0
Presence or absence of ST segment abnormalities
Day 0
Evaluation by resting ECG of rhythmic risk marker : QRS fragmentation
Lasso di tempo: Day 0
Presence or absence of QRS fragmentation
Day 0
Evaluation by resting ECG of rhythmic risk marker : ventricular extrasystoles (VES)
Lasso di tempo: Day 0
Presence or absence of VES. Ventricular extrasystoles especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex forms (repetitive, several morphologies, instantaneous cycle >200bpm)
Day 0
Evaluation by resting ECG of rhythmic risk marker : ventricular tachycardia (VT)
Lasso di tempo: Day 0
Presence or absence of VT.
Day 0
Presence of rhythmic risk markers bye the stress test
Lasso di tempo: Day 0
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, several morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VT). The analysis focus on the exercise period, and the recovery period. Ventricular arrhythmias will be quantified.
Day 0
Presence of rhythmic risk markers bye ECG holter
Lasso di tempo: Day 0
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, multiple morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VTs). Ventricular arrhythmias are quantified.
Day 0
Presence of rhythmic risk markers bye ECG monitoring during games and trainings
Lasso di tempo: Day 0
In case of moderate arrhythmia on stress test and/or Holter ECG, ECG monitoring during training sessions and matches is carried out with analysis of the tracings collected, in search of more sustained arrhythmia, particularly at the ventricular level.
Day 0
Presence of rhythmic risk markers by pharmacological tests and/or electrophysiological exploration
Lasso di tempo: Day 0
If the risk is perceived as very high, pharmacological tests (Isuprel®) and/or electrophysiological exploration may be performed during hospitalization, in search of dangerous rhythm disorders, particularly at the ventricular level.
Day 0

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Presence of myocardial fibrosis by injected MRI
Lasso di tempo: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The presence or absence of myocardial fibrosis is evaluated.
Month 3
Presence of transmural localization of myocardial fibrosis by injected MRI
Lasso di tempo: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The presence or absence of transmural localization is evaluated.
Month 3
Measurement of cardiac scar size by injected MRI
Lasso di tempo: Month 3
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed. The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology. The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm. The images are reviewed by a core lab at the Bordeaux University Hospital. The size of scars is measured in milliliters (mL).
Month 3
Search for constitutional genetic biomarkers
Lasso di tempo: Month 5
identification by sequencing of genetic variants that could have an impact on the occurrence of a severe form in individuals infected with SARS-CoV-2.
Month 5
Research of inflammation markers
Lasso di tempo: Month 5
Th1/Th2/activation/inflammation/apoptosis markers are measured in sera by a Luminex test allowing the detection of 10 analytes with a commercial kit according to the manufacturer's instructions
Month 5

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

University Hospital, Bordeaux

Investigatori

  • Cattedra di studio: Antoine BENARD, MD, University Hospital, Bordeaux
  • Investigatore principale: Laurent Chevalier, MD, Medical Center of the Bordeaux-Mérignac Sports Clinic

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 giugno 2020

Completamento primario (Effettivo)

2 marzo 2021

Completamento dello studio (Effettivo)

2 marzo 2021

Date di iscrizione allo studio

Primo inviato

2 giugno 2021

Primo inviato che soddisfa i criteri di controllo qualità

22 giugno 2021

Primo Inserito (Effettivo)

23 giugno 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 giugno 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 giugno 2021

Ultimo verificato

1 giugno 2021

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • CHUBX 2020/16

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su COVID-19

Prove cliniche su Resting electrocardiogram

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Vietnam

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi